Aquestive Therapeutics, Inc. (AQST), Monday announced that the U.S. Food and Drug Administration has accepted the company's New Drug Application for Anaphylm for the treatment of Type 1 allergic reactions.
Also, the agency has assigned a Prescription Drug User Fee Act target action date of January 31, 2026.
The company further stated that the FDA might decide to conduct an Advisory Committee meeting for the approval of Anaphylm.
If approved, Anaphylm would be the first and only orally delivered epinephrine option for the treatment of severe allergic reactions in the United States.
In the pre-market hours, AQST is trading at $3.69, up 7.89 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.